Randomized Trial: Trastuzumab for 6 Months as Good as Treatment for 12 Months in Patients with HER2-positive Early Breast Cancer
17 Jun, 2019 | 01:30h | UTCCommentaries: Is the duration of adjuvant trastuzumab debate still clinically relevant? – The Lancet (free) AND 6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return – University of Warwick (free)